The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients

Combination therapy of Ezetimibe (10 mg/day) and Simvastatin (40 mg/day) was more effective than mono-therapy with Simvastatin (40 mg/day) on reducing LDL-C, TG and hs-CRP level in percutaneous coronary intervention patients, leading to more significant anti-inflammatory effect.